Detailed information for compound 310876

Basic information

Technical information
  • TDR Targets ID: 310876
  • Name: 4-[[4-[4-[(Z)-2-cyanoethenyl]-2,6-dimethylani lino]pyrimidin-2-yl]amino]benzonitrile
  • MW: 366.419 | Formula: C22H18N6
  • H donors: 2 H acceptors: 4 LogP: 4.55 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: N#C/C=C\c1cc(C)c(c(c1)C)Nc1ccnc(n1)Nc1ccc(cc1)C#N
  • InChi: 1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3-
  • InChiKey: YIBOMRUWOWDFLG-ARJAWSKDSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 4-[[4-[4-[(Z)-2-cyanovinyl]-2,6-dimethyl-anilino]pyrimidin-2-yl]amino]benzonitrile
  • 4-[[4-[4-[(Z)-2-cyanovinyl]-2,6-dimethylanilino]-2-pyrimidinyl]amino]benzonitrile
  • 4-[[4-[[4-[(Z)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzenecarbonitrile
  • Rilpivirine
  • 4-[[4-[[4-[(Z)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]pyrimidin-2-yl]amino]benzonitrile
  • 4-[[4-[[4-[(Z)-2-cyanovinyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
  • 4-[[4-[[4-[(Z)-2-cyanovinyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
  • 4-[[4-[[4-[(Z)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile
  • 4-{4-[4-((Z)-2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile
  • AIDS-169045
  • AIDS169045
  • TMC278(Z-ISOMER)

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus granulosus integrin alpha ps 0.0224 0.0405 0.0405
Brugia malayi Integrin alpha pat-2 precursor 0.0499 0.1824 1
Loa Loa (eye worm) hypothetical protein 0.0199 0.0278 0.0865
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Mycobacterium leprae PROBABLE HYDROLASE 0.0243 0.0502 1
Leishmania major hypothetical protein, conserved 0.0757 0.3155 1
Schistosoma mansoni integrin alpha 0.0499 0.1824 1
Schistosoma mansoni integrin alpha-ps 0.0224 0.0405 0.2218
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Loa Loa (eye worm) matrixin family protein 0.0442 0.1529 0.4754
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Mycobacterium tuberculosis Probable peptidoglycan hydrolase 0.0243 0.0502 1
Schistosoma mansoni hypothetical protein 0.0282 0.0708 0.3879
Mycobacterium ulcerans hydrolase 0.0243 0.0502 1
Brugia malayi Hemopexin family protein 0.0282 0.0708 0.3879
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Echinococcus multilocularis integrin alpha ps 0.0224 0.0405 0.0405
Loa Loa (eye worm) hypothetical protein 0.0243 0.0502 0.1561
Loa Loa (eye worm) matrix metalloproteinase 0.0199 0.0278 0.0865
Echinococcus multilocularis integrin alpha 3 0.0382 0.1224 0.1224
Treponema pallidum fructose-bisphosphate aldolase 0.0319 0.0895 0.5
Giardia lamblia Fructose-bisphosphate aldolase 0.0319 0.0895 1
Loa Loa (eye worm) hypothetical protein 0.0392 0.1271 0.3951
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Entamoeba histolytica fructose-1,6-bisphosphate aldolase, putative 0.0319 0.0895 1
Trypanosoma cruzi hypothetical protein, conserved 0.0729 0.3011 1
Echinococcus multilocularis matrix metallopeptidase 7 (M10 family) 0.0724 0.2986 0.2986
Onchocerca volvulus Matrix metalloproteinase homolog 0.0442 0.1529 1
Entamoeba histolytica fructose-1,6-bisphosphate aldolase, putative 0.0319 0.0895 1
Trypanosoma brucei RNA helicase, putative 0.0167 0.0111 1
Echinococcus multilocularis integrin alpha ps 0.0224 0.0405 0.0405
Schistosoma mansoni hypothetical protein 0.0167 0.0111 0.0607
Brugia malayi Integrin alpha cytoplasmic region family protein 0.0377 0.1197 0.6564
Loa Loa (eye worm) hypothetical protein 0.0199 0.0278 0.0865
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Loa Loa (eye worm) hypothetical protein 0.0275 0.0671 0.2084
Onchocerca volvulus 0.0282 0.0708 0.3431
Loa Loa (eye worm) hypothetical protein 0.0199 0.0278 0.0865
Loa Loa (eye worm) matrixin family protein 0.0482 0.1735 0.5392
Echinococcus granulosus matrix metallopeptidase 7 M10 family 0.0724 0.2986 0.2986
Echinococcus multilocularis DNA dependent protein kinase catalytic subunit 0.2084 1 1
Loa Loa (eye worm) hypothetical protein 0.0377 0.1197 0.3722
Toxoplasma gondii target of rapamycin (TOR), putative 0.0145 0 0.5
Brugia malayi Matrix metalloprotease, N-terminal domain containing protein 0.0243 0.0502 0.2753
Trichomonas vaginalis fructose-bisphosphate aldolase, putative 0.0319 0.0895 1
Schistosoma mansoni matrix metallopeptidase-7 (M10 family) 0.0199 0.0278 0.1526
Brugia malayi Matrixin family protein 0.0199 0.0278 0.1526
Onchocerca volvulus Matrilysin homolog 0.0442 0.1529 1
Echinococcus granulosus integrin alpha 3 0.0382 0.1224 0.1224
Brugia malayi Matrixin family protein 0.0482 0.1735 0.9511
Loa Loa (eye worm) integrin alpha pat-2 0.0769 0.3217 1

Activities

Activity type Activity value Assay description Source Reference
CC50 (ADMET) = 30000 nM Cytotoxic concentration of the compound was determined against wild type human immunodeficiency virus type 1 LA1 strain ChEMBL. 15771449
EC50 (functional) = 0.6 nM Effective concentration of the compound was determined for the inhibition of wild type human immunodeficiency virus type 1 LAI strain ChEMBL. 15771449
EC50 (functional) = 1.6 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 103N ChEMBL. 15771449
EC50 (functional) = 4 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 227L+106A ChEMBL. 15771449
EC50 (functional) = 4 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 227C ChEMBL. 15771449
EC50 (functional) = 5 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 181C ChEMBL. 15771449
EC50 (functional) = 6.3 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 100I ChEMBL. 15771449
EC50 (functional) = 31 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 188L ChEMBL. 15771449
EC50 (functional) = 39.8 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 103N+181C ChEMBL. 15771449
EC50 (functional) = 794 nM Effective concentration of the compound was determined against human immunodeficiency virus type 1 mutated at 100I+103N ChEMBL. 15771449
Selectivity index (functional) = 50000 Ratio of CC50 and EC50 of the compound against wild type human immunodeficiency virus type 1 LAI strain ChEMBL. 15771449

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.